SlideShare a Scribd company logo
1 of 32
Διαλύματα Κιτρικών στη Χρόνια Αιμοκάθαρση Χρήστος Αργυρόπουλος Οκτώβριος 2010
Διαλύματα Κιτρικών στην συνεχή Α/Κ Ι ,[object Object],[object Object],[object Object],[object Object]
Κύκλωμα  CRRT  με περιοχική αντιπηξία με κιτρικά  (RCA)
Συστηματικές Επιπλοκές & Πιθανά προβλήματα ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Κιτρικά στη Χρόνια Α/Κ ,[object Object],[object Object],[object Object],[object Object],[object Object]
Διαφορές πρωτοκόλλων κιτρικών μεταξύ χρόνιας και οξείας Α/Κ ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Citrasate®
Κλινικά Αποτελέσματα χρήσης  Citrasate®  στη χρόνια Α/Κ
Επάρκεια Κάθαρσης σε Χρόνια Α/Κ με κιτρικά ,[object Object],[object Object],[object Object],[object Object],[object Object],Clin J Am Soc Nephrol 4: 1459-1464, 2009
Χρησιμοποιηθέντα Διαλύματα  Clin J Am Soc Nephrol 4: 1459-1464, 2009
Χαρακτηριστικά Ασθενών Clin J Am Soc Nephrol 4: 1459-1464, 2009
Επάρκεια κάθαρσης ουρίας  Clin J Am Soc Nephrol 4: 1459-1464, 2009 Όλοι οι Ασθενείς Υποομαδα ασθενών με χαμηλή δόση Α/Κ
Επάρκεια Κάθαρσης ουρίας και β-2 Μικροσφαιρίνης Clin J Am Soc Nephrol 4: 1459-1464, 2009 Η  β-2  μικροσφαιρίνη στο τέλος της περιόδου αιμοκάθαρσης με συμβατικά διαλύματα αιμοκάθαρσης μειώθηκε με τη χρήση διαλύματος Κιτρικών από  28.1 ± 10.0  σε  25.9 ± 10.0 mg/L   ( P  < 0.0001)
Βιοχημικές Παράμετροι Clin J Am Soc Nephrol 4: 1459-1464, 2009
Επίπεδα αλουμινίου Clin J Am Soc Nephrol 4: 1459-1464, 2009
Συμπεράσματα ,[object Object],[object Object],Clin J Am Soc Nephrol 4: 1459-1464, 2009
Κριτική ,[object Object],[object Object],[object Object]
Κιτρικά σε Αιμοδυναμικές, Βιοχημικές και παράμετρους πηκτικότητας BMC Nephrology  2009,  10 :7
Ερευνητικό Πρωτόκολλο BMC Nephrology  2009,  10 :7
Σύσταση Διαλυμάτων BMC Nephrology  2009,  10 :7 Α C C+ Na (mol/L) 138 138 138 K(mmol/L) 2 2 2 Glu (mmol/L) 5.5 5.5 5.5 Mg(mmol/L) 0.5 0.5 0.5 O ξικά ( mmol/L) 3 0.3 0.3 Κιτρικά  (mmol/L) 0 0.8 0.8 Ca(mmol/L) 1.25 1.50 1.25 1.50 1.50 1.75
Ασθενείς και Στοιχεία Α/Κ ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],BMC Nephrology  2009,  10 :7
Αιμοδυναμικές Παράμετροι BMC Nephrology  2009,  10 :7 Αρτηριακή Πίεση : μετρήθηκε κάθε 30 λεπτά με το πιεσόμετρο των 4008Β Όγκος παλμού : Μετρήθηκε από το ολοκλήρωμα της φάσης άνοδου της κυματορφής παλμού και της δίκροτης εντομής Περιφερικές Αντιστάσεις :
Προφίλ ΑΠ στη διάρκεια της ΑΚ BMC Nephrology  2009,  10 :7
Προφίλ ΑΠ Υπερτασικών ασθενών στη διάρκεια της ΑΚ BMC Nephrology  2009,  10 :7 (-7.8 mmHg; P < 0.05)
Προφίλ Αιμοδυναμικών παραμέτρων στη διάρκεια της ΑΚ Ι BMC Nephrology  2009,  10 :7
Προφίλ Αιμοδυναμικών παραμέτρων στη διάρκεια της ΑΚ ΙΙ BMC Nephrology  2009,  10 :7
Οξεοβασική Ισορροπία και Επάρκεια Κάθαρσης BMC Nephrology  2009,  10 :7
Οξεοβασική Ισορροπία και Επάρκεια Κάθαρσης BMC Nephrology  2009,  10 :7
Μεταβολισμός Ασβεστίου BMC Nephrology  2009,  10 :7
Προφίλ Πηκτικότητας BMC Nephrology  2009,  10 :7 Συμπλέγματα θρομβίνης – αντιθρομβίνης και θραύσματα θρομβίνης 1+2 : δείκτες ενεργοποίησης του πηκτικού μηχανισμού
Συμπεράσματα ,[object Object],[object Object],[object Object],[object Object],[object Object],BMC Nephrology  2009,  10 :7
Κριτική - περιθώριο για περαιτέρω μελέτες ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],BMC Nephrology  2009,  10 :7

More Related Content

What's hot

chronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxchronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxHuda693686
 
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...NephroTube - Dr.Gawad
 
Dialysis in elderly patients wkd 2014
Dialysis in elderly patients wkd 2014Dialysis in elderly patients wkd 2014
Dialysis in elderly patients wkd 2014Muhamed Al Rohani
 
Anemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadAnemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadNephroTube - Dr.Gawad
 
Sglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseasesSglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseasesChristos Argyropoulos
 
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...Dr Nick
 
Is it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. GawadIs it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. GawadNephroTube - Dr.Gawad
 
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21CRISTOBAL MORALES PORTILLO
 
Hif ph inhibitors for anemia in ckd
Hif ph inhibitors for anemia in ckdHif ph inhibitors for anemia in ckd
Hif ph inhibitors for anemia in ckdHarsh shaH
 
Renal Replacement therapy (Dialytic Management) in AKI - Dr.Gawad
Renal Replacement therapy (Dialytic Management) in AKI - Dr.GawadRenal Replacement therapy (Dialytic Management) in AKI - Dr.Gawad
Renal Replacement therapy (Dialytic Management) in AKI - Dr.GawadNephroTube - Dr.Gawad
 
Linking HFpEF and Chronic kidney disease
Linking HFpEF and Chronic kidney disease    Linking HFpEF and Chronic kidney disease
Linking HFpEF and Chronic kidney disease magdy elmasry
 
ESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadNephroTube - Dr.Gawad
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementPraveen Nagula
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...SYEDRAZA56411
 

What's hot (20)

chronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxchronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptx
 
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...
SGLT2-i, DPP4-i & Incretin Mimetics (Optimizing their use in CKD Patients) - ...
 
Dialysis in elderly patients wkd 2014
Dialysis in elderly patients wkd 2014Dialysis in elderly patients wkd 2014
Dialysis in elderly patients wkd 2014
 
Erythropoietins (Epoetins)
Erythropoietins (Epoetins)Erythropoietins (Epoetins)
Erythropoietins (Epoetins)
 
Anemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadAnemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. Gawad
 
Sglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseasesSglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseases
 
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
 
Is it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. GawadIs it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. Gawad
 
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21
SGLT2 CONGRESO PERUANO DE ENDOCRINOLOGIA 14ago21
 
Hif ph inhibitors for anemia in ckd
Hif ph inhibitors for anemia in ckdHif ph inhibitors for anemia in ckd
Hif ph inhibitors for anemia in ckd
 
Renal Replacement therapy (Dialytic Management) in AKI - Dr.Gawad
Renal Replacement therapy (Dialytic Management) in AKI - Dr.GawadRenal Replacement therapy (Dialytic Management) in AKI - Dr.Gawad
Renal Replacement therapy (Dialytic Management) in AKI - Dr.Gawad
 
Direct oral anticoagulant
Direct oral anticoagulantDirect oral anticoagulant
Direct oral anticoagulant
 
Linking HFpEF and Chronic kidney disease
Linking HFpEF and Chronic kidney disease    Linking HFpEF and Chronic kidney disease
Linking HFpEF and Chronic kidney disease
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021Diabetic kidney disease 2021
Diabetic kidney disease 2021
 
ESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. Gawad
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes management
 
SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
 
CRRT in ICU - AKI - Dr. Gawad
CRRT in ICU - AKI - Dr. GawadCRRT in ICU - AKI - Dr. Gawad
CRRT in ICU - AKI - Dr. Gawad
 
SGLT2 inhibitors - what's new?
SGLT2 inhibitors - what's new?SGLT2 inhibitors - what's new?
SGLT2 inhibitors - what's new?
 

Similar to Citric Acid Dialysate in Hemodialysis (in Greek)

4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.isrodoy isr
 
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσης
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσηςΣύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσης
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσηςAthanasios Nousis
 
Vakalis Radiotherapy Of Lung
Vakalis Radiotherapy Of LungVakalis Radiotherapy Of Lung
Vakalis Radiotherapy Of Lungfondas vakalis
 
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...Dimitris P. Korkolis
 
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρεςLoucas Nicolaou
 
Χημεία Κρασιού
Χημεία ΚρασιούΧημεία Κρασιού
Χημεία Κρασιούguest3bab59
 
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow up
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow upChronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow up
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow upGeorgia Bardi
 

Similar to Citric Acid Dialysate in Hemodialysis (in Greek) (9)

4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ Ακτινοθεραπεία - NSCLC.
 
Rectal ca -Vakalis.X
Rectal ca -Vakalis.XRectal ca -Vakalis.X
Rectal ca -Vakalis.X
 
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσης
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσηςΣύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσης
Σύγχρονες τεχνολογίες στη διαδικασία θεραπευτικής αφαίρεσης
 
Vakalis Radiotherapy Of Lung
Vakalis Radiotherapy Of LungVakalis Radiotherapy Of Lung
Vakalis Radiotherapy Of Lung
 
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...
Η Χειρουργική Αντιμετώπιση των Ηπατικών Μεταστάσεων από Κολοορθικό Καρκίνο - ...
 
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες
11 ς 2015 3 28 ομ 1 πάν. κουρουνάκης βιολογικό στρες
 
Χημεία Κρασιού
Χημεία ΚρασιούΧημεία Κρασιού
Χημεία Κρασιού
 
Anal ca vakalis
Anal  ca vakalisAnal  ca vakalis
Anal ca vakalis
 
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow up
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow upChronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow up
Chronic Myeloid Leukemia (CML) Cytogenetic diagnosis and follow up
 

More from Christos Argyropoulos

Secondary Hyperparathyroidism in Kidney Transplantation
Secondary Hyperparathyroidism in Kidney TransplantationSecondary Hyperparathyroidism in Kidney Transplantation
Secondary Hyperparathyroidism in Kidney TransplantationChristos Argyropoulos
 
Management of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxManagement of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxChristos Argyropoulos
 
Kidney Disease In patients living with HIV
Kidney Disease In patients living with HIVKidney Disease In patients living with HIV
Kidney Disease In patients living with HIVChristos Argyropoulos
 
RNA Biomarkers in Chronic Kidney Disease
RNA Biomarkers in Chronic Kidney DiseaseRNA Biomarkers in Chronic Kidney Disease
RNA Biomarkers in Chronic Kidney DiseaseChristos Argyropoulos
 
Aldosterone in diabetes and other kidney diseases
Aldosterone in diabetes and other kidney diseasesAldosterone in diabetes and other kidney diseases
Aldosterone in diabetes and other kidney diseasesChristos Argyropoulos
 
Survival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsSurvival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsChristos Argyropoulos
 
Diabetic kidney disease 2021 all_slides
Diabetic kidney disease 2021 all_slidesDiabetic kidney disease 2021 all_slides
Diabetic kidney disease 2021 all_slidesChristos Argyropoulos
 
Acute Kidney Injury in Patients with Cancer
Acute Kidney Injury in Patients with CancerAcute Kidney Injury in Patients with Cancer
Acute Kidney Injury in Patients with CancerChristos Argyropoulos
 
Hyperparathyroidism after kidney transplantation
Hyperparathyroidism after kidney transplantationHyperparathyroidism after kidney transplantation
Hyperparathyroidism after kidney transplantationChristos Argyropoulos
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseChristos Argyropoulos
 
Involuntary discharges from the dialysis unit
Involuntary discharges from the dialysis unitInvoluntary discharges from the dialysis unit
Involuntary discharges from the dialysis unitChristos Argyropoulos
 
Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)Christos Argyropoulos
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itChristos Argyropoulos
 
Relative Blood Volume Monitoring and Applications in Dialysis
Relative Blood Volume Monitoring and Applications in DialysisRelative Blood Volume Monitoring and Applications in Dialysis
Relative Blood Volume Monitoring and Applications in DialysisChristos Argyropoulos
 

More from Christos Argyropoulos (20)

Secondary Hyperparathyroidism in Kidney Transplantation
Secondary Hyperparathyroidism in Kidney TransplantationSecondary Hyperparathyroidism in Kidney Transplantation
Secondary Hyperparathyroidism in Kidney Transplantation
 
Management of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxManagement of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptx
 
Kidney Disease In patients living with HIV
Kidney Disease In patients living with HIVKidney Disease In patients living with HIV
Kidney Disease In patients living with HIV
 
RNA Biomarkers in Chronic Kidney Disease
RNA Biomarkers in Chronic Kidney DiseaseRNA Biomarkers in Chronic Kidney Disease
RNA Biomarkers in Chronic Kidney Disease
 
Diabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 UpdateDiabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 Update
 
Aldosterone in diabetes and other kidney diseases
Aldosterone in diabetes and other kidney diseasesAldosterone in diabetes and other kidney diseases
Aldosterone in diabetes and other kidney diseases
 
Survival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive ModelsSurvival Analysis With Generalized Additive Models
Survival Analysis With Generalized Additive Models
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021 Diabetic kidney disease 2021
Diabetic kidney disease 2021
 
Diabetic kidney disease 2021 all_slides
Diabetic kidney disease 2021 all_slidesDiabetic kidney disease 2021 all_slides
Diabetic kidney disease 2021 all_slides
 
Acute Kidney Injury in Patients with Cancer
Acute Kidney Injury in Patients with CancerAcute Kidney Injury in Patients with Cancer
Acute Kidney Injury in Patients with Cancer
 
Telenephrology
TelenephrologyTelenephrology
Telenephrology
 
Hyperparathyroidism after kidney transplantation
Hyperparathyroidism after kidney transplantationHyperparathyroidism after kidney transplantation
Hyperparathyroidism after kidney transplantation
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
 
Chronic Kidney Disease Update 2019
Chronic Kidney Disease Update 2019Chronic Kidney Disease Update 2019
Chronic Kidney Disease Update 2019
 
Involuntary discharges from the dialysis unit
Involuntary discharges from the dialysis unitInvoluntary discharges from the dialysis unit
Involuntary discharges from the dialysis unit
 
Update on diabetic nephropathy 2019
Update on diabetic nephropathy 2019Update on diabetic nephropathy 2019
Update on diabetic nephropathy 2019
 
Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
 
Relative Blood Volume Monitoring and Applications in Dialysis
Relative Blood Volume Monitoring and Applications in DialysisRelative Blood Volume Monitoring and Applications in Dialysis
Relative Blood Volume Monitoring and Applications in Dialysis
 
Chronic Kidney Disease
Chronic Kidney DiseaseChronic Kidney Disease
Chronic Kidney Disease
 

Citric Acid Dialysate in Hemodialysis (in Greek)